Core Viewpoint - Soligenix, Inc. has received orphan drug designation from the European Commission for SGX945, a treatment for Behçet's Disease, following positive Phase 2a clinical results demonstrating biological efficacy and safety [1][3] Group 1: Orphan Drug Designation - The European Commission granted orphan drug designation to dusquetide for Behçet's Disease, which provides a 10-year marketing exclusivity period in the EU after product approval [2] - Orphan designation offers incentives for protocol assistance from the EMA and direct access to the centralized authorization procedure [2] Group 2: Clinical Results and Efficacy - The Phase 2a study of SGX945 showed a 40% improvement in the mean number of ulcers compared to placebo, which is higher than the 37% improvement seen with apremilast in a Phase 3 study [6][7] - The improvement with SGX945 was sustained, showing a 32% improvement at Week 8 after treatment ended at Week 4, while apremilast showed a 41% improvement at Week 8 with continuous administration [6][7] Group 3: Patient Population and Unmet Need - Behçet's Disease affects approximately 18,000 people in the U.S., 50,000 in Europe, and up to 1 million people worldwide, indicating a significant unmet medical need [3][10] - The disease is characterized by painful symptoms that severely impact patients' quality of life, with no current cure available [9][11] Group 4: Mechanism of Action and Safety - Dusquetide, the active ingredient in SGX945, is an innate defense regulator that modulates the body's immune response to promote healing and reduce inflammation [4] - The drug has demonstrated safety and tolerability in a Phase 1 study with 84 healthy volunteers, and no treatment-related adverse events were reported in the Phase 2a study [5][7] Group 5: Intellectual Property and Development - Soligenix holds a strong intellectual property position for dusquetide and related analogs, which enhances its competitive edge in the market [8] - The company is also developing other products targeting rare diseases, indicating a diversified pipeline focused on unmet medical needs [12]

Core Viewpoint - AIM ImmunoTech Inc. has received full approval for a Japanese patent covering the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer, which is expected to see a significant increase in burden by 2030 [1][2]. Group 1: Patent and Intellectual Property - The Japanese patent covers the use of Ampligen in combination with checkpoint inhibitors for treating various cancer types, including pancreatic cancer [2]. - AIM holds additional patents in the U.S. and the Netherlands for similar uses of Ampligen, with expiration dates in August 2039 and December 2039, respectively [2]. - The company plans to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in treating pancreatic cancer, complementing existing designations in the U.S. and EU [3]. Group 2: Market Context and Strategy - Japan is identified as a key global market for health, with significant expected increases in pancreatic cancer cases by 2030 [1]. - The company emphasizes its commitment to developing Ampligen for late-stage pancreatic cancer, addressing a critical unmet health need [3]. - The patent's approval is part of AIM's broader development and commercialization strategy [3]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator that has demonstrated broad-spectrum activity in clinical trials [4].

Core Insights - Keros Therapeutics, Inc. is advancing its lead asset, rinvatercept, targeting neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD), with a focus on improving muscle and bone outcomes through modulation of the transforming growth factor-beta pathway [1][4] Development Updates - A recent phase I update, orphan drug designation, and plans for a phase II trial starting in Q2 2026 have positioned rinvatercept as a central narrative for the company [2][10] - The FDA granted orphan drug designation to rinvatercept for DMD in August 2025, which is expected to streamline the development strategy and regulatory path [7][8] Mechanism of Action - Rinvatercept (KER-065) is designed to selectively inhibit transforming growth factor-beta ligands, including myostatin and activin A, which are negative regulators of muscle and bone mass [3] - By blocking these pathways, the company aims to promote muscle regeneration, increase muscle size and strength, reduce fat accumulation, and enhance bone strength [4] Competitive Landscape - Keros highlights that glucocorticoids are the current standard of care for DMD but have significant side effects, creating an opportunity for rinvatercept to offer a differentiated therapeutic approach [5][6] - The competitive landscape includes Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc., which have established therapies for DMD, making efficient advancement of rinvatercept critical for investor confidence [13] Clinical Data and Future Plans - Phase I data indicated that rinvatercept was well tolerated, showing benefits in muscle mass, fat reduction, and bone density, which supports its intended mechanism [9][11] - The next key milestone is the initiation of a phase II trial for DMD in Q2 2026, which will be crucial for maintaining momentum and investor interest [12][15] Strategic Focus - Keros has concentrated its efforts on rinvatercept, making execution of this single program a significant driver of investor sentiment, with any delays potentially impacting confidence [14]

Core Insights - Sanofi's Waylirz (rilzabrutinib) has received orphan drug designation from Japan's MHLW for treating IgG4-related disease (IgG4-RD), which is not yet approved for this indication in any market [1][10] Group 1: Orphan Drug Designation Benefits - The orphan drug designation is aimed at therapies for rare diseases affecting fewer than 50,000 people in Japan, providing incentives like priority consultation, tax benefits, subsidies, and priority review [2] - This designation offers Sanofi important regulatory and financial advantages as Waylirz progresses through clinical development for IgG4-RD, a rare disease that can cause progressive organ damage if untreated [3][10] Group 2: Clinical Development and Efficacy - Waylirz is a novel BTK inhibitor designed to treat various rare immune-mediated or inflammatory diseases by restoring immune balance [5] - Positive data from a mid-stage study supported the orphan drug designation, showing that 52-week treatment reduced disease flares and minimized the need for glucocorticoids [6] Group 3: Competitive Landscape - In the ITP indication, Waylirz competes with Amgen's Nplate and Rigel Pharmaceuticals' Tavalisse, which pose significant threats despite differing mechanisms [8] - For IgG4-RD, Waylirz may face competition from Amgen's Uplizna if approved, and in chronic spontaneous urticaria (CSU), it would compete with Dupixent, a blockbuster drug with a strong clinical profile [9]

Core Viewpoint - Sanofi's rilzabrutinib has received orphan drug designation in Japan for the treatment of IgG4-related disease, addressing a significant unmet medical need in this rare condition [1][7]. Group 1: Rilzabrutinib's Designation and Clinical Evaluation - The Ministry of Health, Labour and Welfare in Japan granted orphan drug designation to rilzabrutinib for IgG4-RD, highlighting the limited treatment options available for this rare disease [1]. - Rilzabrutinib was evaluated in a phase 2 study, showing a reduction in disease flares and other markers over 52 weeks, while minimizing the need for glucocorticoids [2]. - The safety profile of rilzabrutinib in the phase 2 study was consistent with previous studies, with no new safety signals observed [2]. Group 2: Broader Applications and Regulatory Status - Rilzabrutinib is being studied for multiple rare immune-mediated diseases and received approval for immune thrombocytopenia (ITP) in the US, EU, and UAE in 2025 [3]. - The drug is currently under regulatory review for ITP in Japan and has received expedited designations for various conditions, including IgG4-RD [3]. - Other than the approved ITP indications, the uses of rilzabrutinib for IgG4-RD and other conditions remain investigational [3]. Group 3: Mechanism and Potential Impact - Rilzabrutinib is a novel, oral, reversible covalent BTK inhibitor that aims to restore immune balance through multi-immune modulation [4]. - The drug targets BTK, which plays a critical role in immune-mediated disease processes, indicating its potential effectiveness in treating several rare diseases [4]. - The global prevalence of IgG4-RD is unknown due to its rarity and diagnostic challenges, emphasizing the need for effective treatments like rilzabrutinib [5]. Group 4: Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [6]. - The company is listed on EURONEXT: SAN and NASDAQ: SNY, indicating its presence in major financial markets [6].

Core Viewpoint - NanoViricides is advancing its broad-spectrum antiviral candidate NV-387, focusing on Mpox clinical development and confirming orphan drug designation filings for multiple indications [1] Company Progress - The company has completed the full clinical trial application to initiate a Phase 2 study of NV-387 in the Democratic Republic of Congo for Mpox, with import permissions secured [2][6] - The Phase 2 study is fully funded, with approximately $5.5 million raised in November and a quarterly spend of about $1.8 million [3][7] Market Context - Despite the WHO lifting the global Public Health Emergency declaration, Mpox cases continue to rise in parts of Africa, indicating a persistent need for development [3][5] - The focus on Mpox was chosen due to its shorter development pathway compared to other diseases like RSV and influenza, which require longer trials [8] Orphan Drug Designation - The company is filing for orphan drug designation for NV-387, which could lead to quicker regulatory approvals and significant benefits such as R&D tax credits and marketing exclusivity [9][11] - Orphan drug designation applications are typically processed within three to four months, and if granted, could allow for accelerated approval after Phase 2 trials [11][12] Potential Market Impact - The drug targets significant markets, including smallpox, Mpox, and measles, with rising measles cases in the US highlighting the need for effective treatments [10]

Core Insights - Rein Therapeutics has received orphan drug designation from the European Medicines Agency (EMA) for its lead drug candidate LTI-03, aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF) [1][2][6] Group 1: Drug Designation and Regulatory Impact - The orphan drug designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP), highlighting the seriousness of IPF and the need for new treatment options [2] - Orphan drug designation in the EU provides regulatory incentives such as reduced development fees, potential market exclusivity, and enhanced development efficiency [4] Group 2: Disease Context and Treatment Landscape - IPF is a rare, progressive lung disease characterized by irreversible scarring of lung tissue, leading to declining lung function and respiratory failure, with existing treatments offering poor outcomes [3] - The EMA's decision was supported by preclinical data showing improved survival and lung function, indicating a clinically relevant advantage of LTI-03 over authorized products [5] Group 3: Company Overview and Future Prospects - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications, with LTI-03 being a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling [7] - The company also has a second product candidate, LTI-01, which has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received orphan drug designation in both the U.S. and EU [7]

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333-292331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrants as Specified in its Charter) ____________________________ | Delaware | 6770 | 86-1314502 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard I ...

Summary of Supernus Pharmaceuticals FY Conference Call Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM:SUPN) - **Event**: 37th Annual Piper Sandler Healthcare Conference - **Date**: December 02, 2025 Key Points Industry and Product Focus - **Product in Focus**: APO-go, a treatment for movement disorders, particularly for patients with advanced Parkinson's disease [1][2] - **Market Demand**: There is significant demand for APO-go, with physicians expressing strong support for the product despite current supply constraints [3][4] Supply Chain Challenges - **Current Situation**: The existing manufacturer is facing capacity issues, unable to meet the overwhelming demand for APO-go [5][6] - **Resolution Efforts**: Supernus is exploring multiple avenues to resolve supply constraints, including discussions with the FDA and potential partnerships with alternative suppliers [2][3][10] - **Timeline for Solutions**: Onboarding a new manufacturer could take several months to a year, depending on regulatory approvals and readiness [7][8][9] Patient Demand and Enrollment - **Patient Enrollment Forms (PEFs)**: Despite supply issues, physicians continue to submit PEFs, indicating ongoing interest in APO-go [14][15] - **Patient Demographics**: Initial demand is primarily from patients with advanced Parkinson's disease who have limited treatment options [19][20] Financial Projections - **Sales Estimates**: Initial peak sales estimates for APO-go are projected between $200 million and $300 million, which may need to be revisited once supply issues are resolved [20][21] - **Long-term Outlook**: The long-term potential for APO-go remains strong, as it offers a unique treatment option not available in the current market [21][22] Competitive Landscape - **Market Competition**: APO-go faces competition from other products like Vyalev and Apokyn, but it serves a different purpose as a rescue medication [25][26] - **Product Differentiation**: APO-go is positioned as a unique treatment option, distinct from traditional therapies like Levodopa [21][22] New Product Developments - **Zurzuvae**: Another product in the portfolio targeting postpartum depression, with significant market potential as it addresses a large unmet need [32][33] - **Sales Strategy**: The sales force is primarily targeting OB-GYNs, with potential for expansion based on market response [34][36] M&A and Future Strategy - **M&A Focus**: Supernus is prioritizing commercial-stage assets and is open to acquiring later-stage development programs [47][48] - **Partnership with Biogen**: There is potential for discussions regarding the buyout of Biogen's 50% stake in Zurzuvae, although both companies are currently committed to the brand [46] Financial Synergies - **Cost Synergies**: Supernus anticipates realizing up to $200 million in annualized synergies from the acquisition of Sage Therapeutics [42] Research and Development - **Early-stage Assets**: Supernus is evaluating early-stage assets from Sage and its own pipeline to determine which programs to advance [43][44] Conclusion Supernus Pharmaceuticals is navigating significant supply chain challenges with its APO-go product while maintaining strong demand and interest from healthcare providers. The company is also expanding its product portfolio with Zurzuvae and exploring strategic M&A opportunities to enhance its market position.

Financial Data and Key Metrics Changes - The combined net revenue for Q3 2025 was approximately $3.1 million, representing a 4% increase compared to Q2 2025 revenue of approximately $3 million [4][18] - Loss from operations decreased by $24,000 from $7.2 million in Q3 2024 to $7.3 million in Q3 2025 [19] - Non-GAAP recurring EBITDA for Q3 2025 was a net loss of $8.9 million, compared to a loss of $9.2 million in Q3 2024 [20] - Net loss attributable to common shareholders decreased by $352,000 from $9.9 million in Q3 2024 to $9.5 million in Q3 2025 [20] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased by approximately 0.9% in Q3 2025 over Q2 2025, but decreased by 3.6% compared to Q3 2024 [18] Company Strategy and Development Direction - The company aims to negotiate business development partnerships for licensed rights to develop and commercialize late-stage health products, focusing on generating non-dilutive funding [5][21] - Key late-stage initiatives include orphan indications of Crofelemer for intestinal failure associated with MVID and cancer therapy-related diarrhea [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about multiple expected near-term catalysts for Crofelemer, viewing them as significant and potentially transformative for patients and stakeholders [21] - The company anticipates that these catalysts will lead to collaborations, business development, and licensing deals, supporting late-stage products and programs towards regulatory approval [21] Other Important Information - Crofelemer has shown a groundbreaking reduction of parenteral support of up to 37% for intestinal failure patients, which is significant given the lack of approved treatments for MVID [8][9] - The company is in discussions with multiple potential animal health partners to expand the use of Canalivia for general diarrhea in dogs [14] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.